PDS Biotechnology (PDSB) Projected to Post Quarterly Earnings on Wednesday

PDS Biotechnology (NASDAQ:PDSB) is anticipated to issue its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.15) per share for the quarter. Parties may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, May 13, 2026 at 8:00 AM ET.

PDS Biotechnology (NASDAQ:PDSB) last posted its quarterly earnings results on Monday, March 30th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.06. On average, analysts expect PDS Biotechnology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

PDS Biotechnology Price Performance

PDSB opened at $1.06 on Wednesday. The stock has a 50-day moving average price of $0.82 and a 200-day moving average price of $0.85. The company has a debt-to-equity ratio of 1.27, a current ratio of 2.98 and a quick ratio of 2.98. The firm has a market cap of $57.66 million, a PE ratio of -1.41 and a beta of 1.51. PDS Biotechnology has a 1 year low of $0.51 and a 1 year high of $1.92.

Institutional Investors Weigh In On PDS Biotechnology

Several large investors have recently bought and sold shares of PDSB. Marshall Wace LLP bought a new stake in PDS Biotechnology in the 2nd quarter worth about $91,000. Jane Street Group LLC bought a new stake in PDS Biotechnology in the 2nd quarter worth about $92,000. Squarepoint Ops LLC increased its holdings in PDS Biotechnology by 116.1% in the 3rd quarter. Squarepoint Ops LLC now owns 291,627 shares of the company’s stock worth $295,000 after buying an additional 156,662 shares in the last quarter. Susquehanna International Group LLP increased its holdings in PDS Biotechnology by 603.7% in the 3rd quarter. Susquehanna International Group LLP now owns 94,344 shares of the company’s stock worth $95,000 after buying an additional 80,937 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in PDS Biotechnology by 8.0% in the 4th quarter. Geode Capital Management LLC now owns 520,398 shares of the company’s stock worth $401,000 after buying an additional 38,399 shares in the last quarter. 26.84% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

PDSB has been the subject of several recent analyst reports. Wall Street Zen raised PDS Biotechnology from a “sell” rating to a “hold” rating in a research report on Saturday, April 4th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of PDS Biotechnology in a research report on Wednesday, April 15th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PDS Biotechnology in a research report on Tuesday, April 21st. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $9.00.

PDS Biotechnology Company Profile

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.